This is a paid press release. Contact the press release distributor directly with any inquiries.
Hemogenyx Pharmaceuticals PLC Announces Half-year Financial Report
- HEMO.L
- 5HU
- HOPHF
Interim Results for the period ended 30 June 2026
LONDON, UK /ACCESS Newswire/ September 28, 2026 /Hemogenyx Pharmaceuticals plc (“Hemogenyx Pharmaceuticals” or the”Company”) (LSE:HEMO), the biopharmaceutical group developing therapies designed to transform blood disease treatment, whose shares are admitted to the equity shares (transition) category of the Official List, announces its unaudited interim results for the six-month period ended 30 June 2026.
All financial amounts are stated in GBP British pounds unless otherwise indicated.
-
Second Annual IND Report submitted to the FDA and encouraging results observed in the three adult patients treated at the first dose level.
-
Trial positioned for dose escalation.
-
Manufacturing for HG-CT-1 established in Estonia in preparation for technology transfer, with a view to early commercialisation with Cellin Technologies OÜ (“Cellin”).
-
Collaboration with Vilnius university hospital Santaros Klinikos on HG-CT-1 clinical application and research.
-
Operating cost base reduced through the outsourcing of HG-CT-1 manufacture to Made Scientific.
-
£5.6 million raised in H1 2026 to support ongoing clinical development.
Fuller details of these developments are contained in the Interim Management Report below.
We are pleased to present the Hemogenyx Pharmaceuticals’ half year report for the six months ended 30 June 2026.
2025 was the year in which Hemogenyx Pharmaceuticals proved it could operate as a clinical-stage company, and that the Company was entering what the Board believed would be the most clinically prolific period in its history. The first half of 2026 has been about converting that position into readiness: completing the manufacturing transition on which dose escalation depends, securing the regulatory clearances needed to treat children as well as adults, building the physical infrastructure for early commercialisation in Europe, and financing the Phase I programme on terms the Board considers acceptable. Each of these was achieved within the period.
These achievements were made in a challenging market environment for small-cap life sciences companies seeking capital. That we were able to raise £5.6 million in the period, including £3.0 million from a small group of institutional investors at the prevailing market bid price, is a reflection both of the progress the Company has made and of the continuing confidence of our shareholders, to whom the Board is grateful.
